<?xml version='1.0' encoding='utf-8'?>
<document id="27825643"><sentence text="[Sofosbuvir and daclatasvir combination therapy in hemodialysis patient with liver transplantation]."><entity charOffset="0-11" id="DDI-PubMed.27825643.s1.e0" text="[Sofosbuvir" /><entity charOffset="16-27" id="DDI-PubMed.27825643.s1.e1" text="daclatasvir" /><pair ddi="false" e1="DDI-PubMed.27825643.s1.e0" e2="DDI-PubMed.27825643.s1.e0" /><pair ddi="false" e1="DDI-PubMed.27825643.s1.e0" e2="DDI-PubMed.27825643.s1.e1" /></sentence><sentence text="We report a case of sustained remission of a liver transplant patient infected with hepatitis C virus (HCV) genotype 1 undergoing hemodialysis treatment" /><sentence text=" Oral treatment regimen of the HCV infection consists of a combination of sofosbuvir 400 mg after each hemodialysis session and daclatasvir 60 mg daily, for a period of 3 months"><entity charOffset="74-84" id="DDI-PubMed.27825643.s3.e0" text="sofosbuvir" /><entity charOffset="128-139" id="DDI-PubMed.27825643.s3.e1" text="daclatasvir" /><pair ddi="false" e1="DDI-PubMed.27825643.s3.e0" e2="DDI-PubMed.27825643.s3.e0" /><pair ddi="false" e1="DDI-PubMed.27825643.s3.e0" e2="DDI-PubMed.27825643.s3.e1" /></sentence><sentence text=" Laboratory testing indicate that the combination regimen was well-tolerated with no sign of drug-drug interaction" /><sentence text=" Confirmation of these clinical observations in large clinical studies may help improve morbidity and decrease mortality outcome in patients infected with HCV and undergoing hemodialysis treatment" /><sentence text="" /></document>